Trial Profile
The combination treatment of laser induced chorioretinal venous anastomosis and Lucentis for macula oedema that is secondary to central retinal vein occlusion, compared to the published results of Lucentis treatment only, a phase IV study.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 10 Aug 2021
Price :
$35
*
At a glance
- Drugs Ranibizumab (Primary)
- Indications Retinal oedema
- Focus Therapeutic Use
- Acronyms L-CVBS Extension Study
- 06 Aug 2021 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 23 Jan 2019 Planned End Date changed from 31 Dec 2019 to 31 Dec 2022.
- 11 Apr 2018 Planned End Date changed from 31 Dec 2017 to 31 Dec 2019.